Ferric Carboxymaltose

Indications

Ferric carboxymaltose is an iron replacement therapy specifically indicated for patients aged one year and older who suffer from iron deficiency anemia and have an intolerance or inadequate response to oral iron treatments. Additionally, it is prescribed for adult patients with iron deficiency in non-dialysis-dependent chronic kidney disease. This formulation is also utilized to address iron deficiency and enhance exercise capacity in adult patients classified under New York Heart Association (NYHA) class II or III heart failure.

Pharmacodynamics

Positron emission tomography (PET) studies have revealed significant red cell uptake of ferric carboxymaltose. For iron deficiency, uptake ranges from 91% to 99%. For renal anemia cases, uptake varies between 61% and 84%, suggesting effective iron absorption by red blood cells across different conditions, with overall uptake percentages between 61% and 99%.

Absorption

Following the administration of a single dose ranging from 100 to 1,000 mg to iron-deficient patients, maximum serum iron concentrations are observed. These concentrations range from 37 μg/mL to 333 μg/mL and are reached within 15 minutes to approximately 1.21 hours post-administration.

Mechanism of Action

Ferric Carboxymaltose functions through a mechanism of action characterized by its composition as a colloidal iron (III) hydroxide complexed with carboxymaltose, a carbohydrate polymer. This formulation is designed to facilitate the release of iron. By delivering controlled and stable quantities of iron, it ensures effective absorption and utilization by the body.